ASH 2024 Myeloma Report | Abstract Finder

Abstract Number: 936 – Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Presenter: Doris K. Hansen, MDSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 4:00 PM–4:15 PMLocation: San Diego Ballroom AB...

Abstract Number: 934 – Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Presenter: Oren Pasvolsky, MDSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 3:30 PM–3:45 PMLocation: San Diego Ballroom AB...

Abstract Number: 933 – Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Presenter: Adeel M Khan, MD, MS, MPHSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 3:15 PM–3:30 PMLocation: San Diego...

Abstract Number: 931 – Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Presenter: Binod Dhakal, MBBSSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 2:45 PM–3:00 PMLocation: San Diego Ballroom AB...

Abstract Number: 923 – A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Presenter: Hua Jiang, PhDSession: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic MalignanciesDate & Time: Monday, December 9, 2024 3:45 PM–4:00 PMLocation: Hall B (San...

Abstract Number: 898 – Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Presenter: Elias K. Mai, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early RelapseDate & Time: Monday, December 9, 2024 3:30 PM–3:45 PMLocation: Pacific Ballroom Salons 24-26...

« Older Entries

Next Entries »

Abstract Number: 936 – Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Abstract Number: 934 – Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Abstract Number: 933 – Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Abstract Number: 931 – Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Abstract Number: 923 – A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Abstract Number: 898 – Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Recent Posts

Recent Comments

Archives

Categories

Meta